查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864074

靶向定序市场按产品类型、平台、最终用户和应用划分－2025年至2032年全球预测

Targeted Sequencing Market by Product Type, Platform, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，标靶定序市场将成长至 339.7 亿美元，复合年增长率为 20.58%。

关键市场统计数据
基准年 2024 76亿美元
预计年份：2025年 91.8亿美元
预测年份 2032 339.7亿美元
复合年增长率 (%) 20.58%

为决策者提供关于标靶定序的简明策略指南，重点在于技术整合、临床效用和营运影响。

化学、仪器和数据分析技术的进步使得标靶定序从一项小众实验室技术发展成为精准研究和临床工作流程的基础。本执行摘要总结了该技术的关键发展、应用模式、监管趋势和竞争动态，旨在帮助研究机构、诊断实验室和生命科学公司的管理人员制定策略重点和投资决策。

以下说明将标靶定序置于更广泛的基因组学生态系统中，其中样本处理能力、检测特异性和生物资讯技术水平决定了其商业性和临床应用的差异化。关键驱动因素包括肿瘤学、遗传性疾病诊断和感染疾病监测领域对精准基因组分析的需求，以及在常规工作流程中对经济高效、高置信度变异检测的需求。同时，不断变化的监管要求和报销机制也在影响检测方法从研究到临床实践的转化。

本导言将标靶定序定位为一个动态的模组化平台，其中仪器、耗材和软体构成整合的端到端解决方案。它强调了互通性和工作流程最佳化的重要性，并指出了组织在平台选择、面板设计和分析流程建构方面所面临的策略选择。本摘要的其余部分详细阐述了技术转折点、外部政策影响、细分市场差异、区域绩效差距，并为希望在这个快速成熟的领域创造价值的领导者提供了具体建议。

化学的进步、可扩展的仪器架构以及日益成熟的生物资讯学正在汇聚，重新定义靶向定序流程中的临床和研究效用。

过去几年，一系列变革正在重塑相关人员开发、部署和利用标靶定序解决方案的方式。首先，化学和样品製备技术的创新缩短了周转时间，提高了标靶效率，使诊断实验室能够提供更快、更可靠的结果。同时，仪器架构也实现了可扩展性，从用于分散式检查的桌上型系统到用于集中式定序中心的高通量平台，拓展了其应用场景，从单例患者诊断扩展到大规模队列研究。

同时，生物资讯学已从辅助角色发展成为一项策略能力。先进的变异检测工具、标准化流程和可解释的註释层正在推动临床层级的解读，并缩短临床医生和研究人员的决策时间。软体和服务日趋成熟，提高了提供整合分析服务的供应商的价值获取，为订阅和按效果付费的经营模式铺平了道路。

市场动态也反映出向模组化生态系的转变，在这个生态系中，试剂、套件和第三方分析工具可以共存。各机构越来越倾向于采用灵活的平台策略，将设备和试剂采购分离，以避免供应商锁定，并保持检测设计的灵活性。同时，定序提供者、试剂开发商和生物资讯公司之间更紧密的合作正在推动捆绑式解决方案的出现，从而加速医院实验室和研究中心对这些解决方案的采用。

监管和报销环境也在影响产品设计和商业推广。强调临床疗效和可追溯性的法规结构迫使医疗机构加强品管体系，产生可靠的检验数据，并儘早与监管机构沟通。同时，支付方开始要求提供更有力的临床效用和成本效益证据才能实现广泛应用，这促使研发人员调整其证据产生策略以适应报销需求。这些变化共同重塑了该领域的竞争格局，并预示着未来不久资本和人才将更加集中。

2025 年关税调整将促进目标定序生态系统的催化作用。

2025年美国关税调整的累积影响已在目标定序价值定序中造成了显着的摩擦，影响了筹资策略、定价和供应连续性。关税相关的成本压力影响了资本设备和耗材，并推高了进口到美国的仪器和试剂的到岸成本。因此，供应商和最终用户重新评估了其采购计划，并加快了供应商多元化，以维持营运预算和专案进度。

为因应这些贸易措施，许多供应商提高了生产在地化程度，具体做法包括将关键生产环节转移到国内工厂，或在免税区寻找替代供应商并进行资格认证。虽然这些调整缓解了进口关税的即时影响，但也需要短期资本投资和供应链检验。一些试剂和套件生产商必须重新认证製造地并复製品管流程，导致前置作业时间延长和批次等效性评估，从而影响了产品供应。

除了製造地转移之外，关税环境也凸显了供应链韧性的策略重要性。各组织更重视库存缓衝、多供应商协议和合约保护，以降低上行风险。此外，采购部门越来越多地采用总到岸成本分析，该分析将关税、合规相关费用和潜在延误纳入考量。这些措施使那些拥有地理位置分散的製造地和强大物流能力的供应商受益。

最后，关税调整也影响了合作和商业性行为。随着供应商和服务供应商寻求分担本地化成本并确保优先获得关键零件，战略伙伴关係和共同投资模式日益受到重视。同时，一些学术和研究机构探索建立试剂共用联盟和集中采购框架，以维持研究的连续性。虽然关税增加了短期成本和营运复杂性，但也促进了供应链现代化，并激励相关人员加强长期韧性策略。

基于深度细分的洞察，将产品架构、平台选择、最终用户优先顺序和应用需求与策略决策流程连结起来。

细分市场分析清晰地区分了技术堆迭、使用者需求和商业性压力，从而指南产品组合和市场推广策略。根据产品类型，市场可分为仪器、试剂和套件以及软体和服务。仪器部分涵盖了从用于分散式和低通量检测的桌上型定序仪到用于中心实验室和大规模研究的高通量定序仪。试剂和套件包括基于扩增子、基于杂合反应和分子反转探针的各种形式，每种形式都针对不同的标靶范围、检体类型和灵敏度要求进行了最佳化。软体服务涵盖生物资讯服务和数据分析软体，反映了对数据解读、流程检验和监管报告日益增长的需求。

平台细分进一步明确了技术权衡和应用适用性。扩增子定序工作流程，包括多重PCR和基于独特分子识别码（UMI）的方法，可为特定标靶和低起始量样本提供高灵敏度。基于诱饵和探针的杂交捕获策略可实现更广泛的标靶覆盖范围，并提高复杂标靶的均一性。分子反转探针专为高通量检测而设计，其中包括针对拷贝数变异分析和单核苷酸多态性检测优化的探针，可为标靶发现和基因型鉴定计划提供经济高效的扩充性。

终端用户细分突显了营运重点和采购模式的差异。学术研究机构（包括公立和私立研究机构）优先考虑方法的灵活性、发表级别的数据品质以及津贴主导的时间节点。医院和诊断中心（包括就地检验和参考实验室）优先考虑法规遵循、可重复性和临床结果的快速交付。製药和生物技术公司（包括临床研究机构和药物研发部门）优先考虑检测方法的稳健性、扩充性临床试验以及与生物标记和伴随诊断项目的整合。

应用细分突显了驱动平台和合作伙伴选择的多样化用例。生物标记发现应用（涵盖药物基因组学和预测性生物标记）需要深度覆盖和高註释准确性。遗传疾病工作流程（包括产前检测和罕见疾病诊断）需要经过验证、伪阴性率低且临床报告清晰的检验。感染疾病应用（抗生素抗药性检测和病原体检测）优先考虑能够适应各种检体基质的快速灵敏的检测方法。肿瘤学应用（诊断、预后和治疗诊断）需要灵活的检测组合设计、与液态生物检体的兼容性以及支援临床决策的分析流程。了解这些细分领域之间的相互依存关係，有助于相关人员将产品开发、商业化和服务交付与明确的技术和临床要求保持一致。

影响美洲、欧洲、中东和非洲以及亚太地区应用和商业化的区域趋势和战略要务：

区域趋势差异显着，影响美洲、欧洲、中东和非洲以及亚太地区的技术应用、监管策略和伙伴关係模式。在美洲，对诊断基础设施的投资以及庞大的临床研究基础正在推动高通量平台和整合生物资讯解决方案的快速普及，这些方案支援转化研究和集中式检测网路。该地区的相关人员优先考虑与当地监管机构的监管协调、临床检验和证据生成，以支持临床应用和支付方参与。

欧洲、中东和非洲地区（EMEA）管理体制的差异和医疗保健资金筹措模式的不同导致了标靶定序应用路径的差异。西方市场往往更注重互通性、标准化数据报告和品管系统，而该地区的新兴市场则更关注可近性、能力建构和成本效益高的工作流程。公私合营倡议和区域参考实验室网路在公共卫生和肿瘤学计画中靶向定序的推广应用方面发挥着至关重要的作用。

亚太地区正经历产能的快速扩张，这主要得益于公共投资、庞大的病患群体以及雄心勃勃的精准医疗倡议。多个国家正大力投资于本地製造、国内研发和国家基因组计划，加速了对用于分散式检查的桌上型系统和用于人群规模研究的高通量平台的需求。在全部区域，全球供应商与本地服务供应商或製造商之间的伙伴关係正在推动技术转移和人才培养，同时也有助于优化产品和服务，以满足监管要求和价格敏感度。

在所有地区，跨国合作、数据协调和监管趋同正成为新兴趋势，推动了跨国临床试验和诊断工具的普及应用。区域基础设施成熟度、支付方政策和本地生产能力持续影响供应商选择和商业策略，凸显了製定市场进入计画时必须考虑区域差异的重要性。

在仪器、试剂和生物资讯学方面的专业知识，结合伙伴关係和服务模式，将决定永续的竞争优势。

公司层面的趋势反映了专业化、整合和服务差异化如何决定竞争定位。专注于仪器创新的供应商强调通量、自动化和从样本到结果的工作流程，以减少人工操作时间并实现分散式检查；而试剂和套件供应商则专注于检测方法的稳健性、批间一致性以及与多个平台的易于集成，以最大限度地满足各种应用场景的需求。

软体和服务供应商正透过提供符合临床解读能力、监管合规性和实验室认证要求的检验流程来脱颖而出。对于希望外包复杂分析并加速临床部署的机构而言，託管服务、云端分析和认证参考资料资料库是关键的价值创造因素。仪器製造商和生物资讯公司之间的策略联盟正在不断扩大，以提供能够缩短检验时间并提高客户维繫的整合解决方案。

新兴企业和专业服务供应商在利基创新领域发挥关键作用，它们开发新型化学方法、客製化捕获探针以及针对难定序标靶的最佳化检测方案。这些规模较小的营业单位通常与大型合作伙伴合作，以实现规模化生产和分销，同时保持产品开发和客户服务的灵活性。同时，受託研究机构(CRO) 和临床 CRO 正在拓展其服务范围，将标靶定序检测方法开发和样本管理服务纳入其中，以满足申办者对端到端研究准备工作流程的需求。

总体而言，成功的公司会将卓越的技术与完善的品质系统、清晰的监管策略以及以客户为中心的商业化模式相结合。随着临床和研究应用的不断成熟，那些投资于证据生成、互通性和灵活商业结构的公司将更有利于获取长期价值。

增强互通性、监管应对力、供应链韧性和实证商业化的实用策略重点

产业领导者应采取全面策略行动，以增强韧性、加速产品应用并抓住高价值机会。首先，应优先考虑平台互通性和开放标准，使客户能够以最小的阻力整合仪器、试剂和检测方法，从而减少采购障碍并扩大目标用户群。其次，应在产品生命週期的早期阶段投资于监管和临床证据建构能力，以加快临床实用化速度并支持医保报销谈判。

第三，我们将实现製造地和采购管道多元化，以降低关税和地缘政治风险，同时确保关键耗材的稳定供应。此外，我们将开发灵活的商业模式，例如试剂即服务、订阅式分析和按绩效付费合同，使供应商的奖励与客户的营运和财务目标保持一致。第四，我们将加强与临床实验室、学术联盟和製药赞助商的合作，促进检测组合的共同开发，并产生真实世界证据，以证明效用。

第五，我们将优先发展生物资讯学和检测检验领域的人才，以维持高标准的分析水平，并加快客户获得洞见的速度。第六，我们将实施严格的品管系统和文件规范，以简化监管申报流程，并促进多司法管辖区的核准。最后，我们将采用以互通性、病患隐私和安全云端架构为重点的资料管治框架，以在确保合规性的同时，实现可扩展的分析。

综合来看，这些努力创造了强大的竞争基础，使产品蓝图与客户需求、监管现实和营运限制保持一致，将技术能力转化为永续的商业性成果。

采用混合方法的研究框架，结合相关利益者访谈、技术文献综述和监管审查，确保研究结果具有情境敏感度和可操作性。

本研究采用结构化访谈、技术检验审查和跨区域政策分析，整合一手和二手研究信息，对靶向定序趋势进行全面评估。研究人员与实验室主任、检测开发人员、采购人员和监管专家进行了初步的定性访谈，以了解营运挑战、应用驱动因素和证据生成策略。这些访谈有助于解读不同平台架构之间的技术权衡，并为商业化和产品开发提供指南。

次要输入资料包括同行评审文献、监管指导文件、临床路径分析以及已发表的技术性能研究，这些研究说明了检测的灵敏度、特异性和工作流程限制。该分析还利用了公开的临床试验註册库、专利申请和会议报告，以绘製创新轨迹并识别新兴的化学技术和分析方法。一项比较政策审查评估了影响临床应用的区域监管要求、品质标准和报销框架。

此分析方法结合了定性综合分析和技术特性、使用者需求及区域驱动因素的交叉基准测试。在检验阶段，研究人员将访谈结果与技术性能声明和监管先例进行交叉核对，以确保结论反映实际应用。研究也承认其局限性，例如由于专有性能数据或商业保密协议的限制，部分内容的可见性受到限制。在适当情况下，研究建议重点强调了适用于各种证据和监管条件的灵活策略。

这种混合方法能够产生可操作的、具有情境感知能力的见解，旨在支援研发规划、商业策略和营运风险管理方面的决策。

整合策略要务和营运指导，将标靶定序的进步转化为持续的临床和商业性影响。

总之，标靶定序技术处于技术能力与临床需求的策略交汇点，提供精准的基因组分析，以支援诊断、治疗和公共卫生应用。化学、仪器和生物资讯学的进步正在拓展该技术的效用，并推动将检测与综合分析相结合的新型商业模式的出现。同时，监管预期、支付方审查和贸易政策等外部因素正在影响产品从研发到常规应用的转换过程。

将产品开发与严谨的证据产生相结合、拥抱供应链多元化并优先考虑互通性的相关人员，将最有利于获取持续价值。区域差异需要量身定制的应对措施：在监管和报销体系支援规模化的地区，集中式高通量方法将更具优势；而桌上型和分散式解决方案则能满足快速照护现场决策的需求。最后，那些将卓越技术与周全的商业性和监管执行相结合的公司，将拥有最大的差异化优势，并与诊断实验室、医疗系统和製药赞助商建立长期伙伴关係。

本执行摘要希望在不断发展的标靶定序领域中优先考虑投资、设计合作项目和管理营运风险的领导者提供策略基础。此处提出的建议和见解旨在支持严谨的决策，并将标靶定序创新快速转化为可衡量的临床和研究成果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 快速整合客製化标靶定序面板，用于精准肿瘤学和个人化治疗决策
  • 在临床实验室中扩大多重标靶定序检测的规模，以实现对微生物病原体的全面检测
  • 新兴的单细胞标靶定序技术揭示肿瘤微环境中的细胞异质性
  • 引入长读长标靶定序方法来检测结构变异和复杂的基因组重排
  • 晶片上微流体靶向定序平台的发展，实现了高通量样本处理和成本降低
  • 扩大标靶定序在非侵入性产前检测的应用，以早期发现胎儿染色体异常
  • 生物资讯流程的进步提高了标靶定序资料分析工作流程的敏感度和特异性
  • 迈向整合标靶定序和数位病理解决方案，实现全面的分子诊断

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的标靶定序市场

  • 装置
    • 桌上型音序器
    • 高通量定序仪
  • 试剂和套件
    • 基于扩增子的套件
    • 杂合反应基础试剂套件
    • MIP基础套件
  • 软体和服务
    • 生物资讯服务
    • 数据分析软体

9. 按平台分類的标靶定序市场

  • 扩增子定序
    • 多重PCR
    • 基于UMI的定序
  • 混合捕获
    • 饵料鲈鱼捕获
    • 基于探针的捕获
  • 分子反转探针
    • 用于 CNV 分析的 MIP 探针
    • 用于SNP检测的MIP探针

第十章 按最终用户分類的标靶定序市场

  • 学术和研究机构
    • 私人研究机构
    • 公共研究机构
  • 医院和诊断中心
    • 就地检验实验室
    • 参考实验室
  • 製药和生物技术公司
    • 临床研究所
    • 药物发现部

第十一章 按应用分類的标靶定序市场

  • 生物标记发现
    • 药物基因组基因生物标誌物
    • 预测性生物标记
  • 遗传性疾病
    • 产前检查
    • 罕见疾病诊断
  • 感染疾病
    • 抗生素抗药性检测
    • 病原体检测
  • 肿瘤学
    • 诊断
    • 预后诊断
    • 治疗诊断学

第十二章 各地区的标靶定序市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的标靶定序市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国标靶定序市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • QIAGEN NV
    • F. Hoffmann-La Roche Ltd
    • BGI Genomics Co., Ltd.
    • Twist Bioscience Corporation
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies plc
    • NeoGenomics, Inc.
Product Code: MRR-1E2F1ED7E6A7

The Targeted Sequencing Market is projected to grow by USD 33.97 billion at a CAGR of 20.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.60 billion
Estimated Year [2025] USD 9.18 billion
Forecast Year [2032] USD 33.97 billion
CAGR (%) 20.58%

A concise strategic orientation to targeted sequencing highlighting technological integration, clinical utility, and operational implications for decision-makers

Targeted sequencing has evolved from a niche laboratory technique into a cornerstone of precision research and clinical workflows, driven by advances in chemistry, instrumentation, and data analytics. This executive summary synthesizes critical developments across technology, adoption patterns, regulatory dynamics, and competitive activity to support senior leaders in research organizations, diagnostics laboratories, and life sciences companies as they weigh strategic priorities and investment decisions.

The narrative that follows positions targeted sequencing within a broader genomics ecosystem where sample throughput, assay specificity, and bioinformatics sophistication now determine commercial and clinical differentiation. Key drivers include the demand for focused genomic interrogation in oncology, inherited disease diagnostics, and infectious disease surveillance, as well as the need for cost-efficient, high-confidence variant detection in routine workflows. At the same time, evolving regulatory expectations and reimbursement frameworks are shaping how assays translate from the bench to bedside.

This introduction frames targeted sequencing as a dynamic, modular platform space where instruments, consumables, and software integrate into end-to-end solutions. It underscores the importance of interoperability and workflow optimization while highlighting the strategic choices that organizations face when selecting platforms, designing panels, and building analytic pipelines. The rest of the summary elaborates on technological inflection points, external policy impacts, segmentation nuances, regional performance differentials, and actionable recommendations for leaders seeking to capture value from this rapidly maturing domain.

How chemistry advances, scalable instrument architectures, and maturing bioinformatics are jointly redefining clinical and research utility across targeted sequencing workflows

The past several years have produced transformative shifts that reshape how stakeholders develop, deploy, and monetize targeted sequencing solutions. First, chemistry and library-preparation innovations have compressed turnaround times and improved on-target efficiency, enabling diagnostics laboratories to deliver faster, higher-confidence results. These technical gains have been paralleled by instrument architectures that scale from benchtop systems for decentralized testing to high-throughput platforms for centralized sequencing hubs, thereby expanding the addressable use-cases from single-patient diagnostics to large-scale cohort studies.

Concurrently, bioinformatics has moved from a supporting role to a strategic capability. Sophisticated variant callers, standardized pipelines, and explainable annotation layers now drive clinical-grade interpretations and reduce time-to-decision for clinicians and researchers. This maturation of software and services increases the value capture for vendors offering integrated analytics and paves the way for subscription or outcome-linked commercial models.

Market dynamics also reflect a shift toward modular ecosystems where reagents, kits, and third-party analytical tools coexist. Organizations increasingly prefer flexible platform strategies that decouple instrument procurement from reagent sourcing to avoid vendor lock-in and maintain agility in assay design. At the same time, partnerships between sequencing providers, reagent developers, and bioinformatics firms have intensified, facilitating bundled solutions that accelerate adoption in hospital laboratories and research centers.

Regulatory and reimbursement landscapes are further influencing product design and commercial rollout. Regulatory frameworks that emphasize clinical validation and traceability have prompted providers to strengthen quality systems, produce robust validation datasets, and engage earlier with regulators. Meanwhile, payers are beginning to demand stronger evidence of clinical utility and cost-effectiveness for broad deployment, encouraging developers to align evidence-generation strategies with reimbursement needs. Taken together, these shifts are redefining the competitive logic of the field and guiding where capital and talent will concentrate in the near term.

How 2025 tariff adjustments catalyzed supply-chain resilience, localization investments, and strategic sourcing shifts across the targeted sequencing ecosystem

The cumulative impact of the United States tariff adjustments implemented in 2025 has introduced measurable friction across the targeted sequencing value chain, influencing sourcing strategies, pricing dynamics, and supply continuity. Tariff-related cost pressures have affected both capital equipment and consumables, elevating landed costs for instruments and reagents imported into the United States. As a result, providers and end users have recalibrated procurement plans and accelerated vendor diversification to maintain operational budgets and program timelines.

In response to these trade measures, many suppliers intensified efforts to localize production, either by shifting key manufacturing steps to domestic facilities or by qualifying alternative suppliers in tariff-exempt jurisdictions. These adjustments reduced immediate exposure to import levies but required short-term capital investments and supply-chain revalidation. For some reagent and kit manufacturers, the need to requalify manufacturing sites and to replicate quality-control processes introduced incremental lead times and batch equivalency assessments that impacted product availability.

Beyond manufacturing shifts, the tariff environment amplified the strategic importance of supply-chain resilience. Organizations placed greater emphasis on inventory buffering, multi-sourcing contracts, and contractual protection clauses to mitigate the risk of sudden cost escalation. Moreover, procurement teams increasingly incorporated total landed cost analyses that accounted for duties, compliance overhead, and potential delays. These practices favored suppliers with geographically distributed manufacturing footprints and robust logistics capabilities.

Finally, the tariff adjustments have influenced collaborative and commercial behaviors. Strategic partnerships and co-investment models gained traction as vendors and service providers sought to share localization costs and to secure preferential access to critical components. Concurrently, some academic and research institutions explored reagent sharing consortia and centralized procurement frameworks to preserve research continuity. While tariffs introduced near-term cost and operational complexity, they also catalyzed supply-chain modernization and encouraged stakeholders to strengthen long-term resilience strategies.

Deep segmentation-driven insights linking product architectures, platform choices, end-user priorities, and application requirements to strategic decision pathways

Segmentation analysis reveals distinct technology stacks, user needs, and commercial pressures that should guide portfolio and go-to-market strategies. Based on product type, the landscape separates into Instruments, Reagents & Kits, and Software & Services. Instruments span benchtop sequencers suited for decentralized, lower-throughput testing and high-throughput sequencers designed for central laboratories and large-scale studies. Reagents and kits include amplicon-based, hybridization-based, and molecular inversion probe formats, each optimized for different target breadths, sample types, and sensitivity requirements. Software and services cover bioinformatics services and data analysis software, reflecting the growing demand for interpretation, pipeline validation, and regulatory-grade reporting.

Platform segmentation further clarifies technical trade-offs and application fit. Amplicon sequencing workflows, including multiplex PCR and unique molecular identifier (UMI)-based approaches, deliver high sensitivity for focused panels and low-input samples. Hybrid capture strategies, realized through baits-based and probe-based capture formats, enable broader panel coverage and improved uniformity for complex targets. Molecular inversion probes are tailored for highly multiplexed detection and include probes optimized for copy-number variation analysis and single-nucleotide polymorphism detection, offering cost-efficient scalability for targeted discovery and genotyping projects.

End-user segmentation highlights differing operational imperatives and procurement patterns. Academic and research institutes, including both private research labs and public research labs, prioritize methodological flexibility, publication-grade data quality, and grant-driven timelines. Hospitals and diagnostic centers, encompassing point-of-care laboratories and reference laboratories, emphasize regulatory compliance, reproducibility, and rapid clinical turnaround. Pharmaceutical and biotechnology companies, including clinical research organizations and drug discovery units, focus on assay robustness, scalability for clinical trials, and integration with biomarker and companion diagnostic programs.

Application segmentation underscores the range of use-cases that drive platform choice and partner selection. Biomarker discovery applications, spanning pharmacogenomic and predictive biomarkers, require deep coverage and high annotation fidelity. Genetic disease workflows, including prenatal testing and rare disease diagnosis, demand validated assays with low false-negative rates and clear clinical reporting. Infectious disease applications-antibiotic resistance testing and pathogen detection-prioritize rapid, sensitive assays that accommodate diverse sample matrices. Oncology applications across diagnostics, prognostics, and theranostics require flexible panel design, compatibility with liquid biopsies, and analytical pipelines that support clinical decision-making. Understanding these segmentation interdependencies enables stakeholders to align product development, commercialization, and service offerings with clearly defined technical and clinical requirements.

Comparative regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping adoption and commercialization

Regional dynamics vary substantially, shaping technology adoption, regulatory strategies, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, investment in diagnostic infrastructure, coupled with a large clinical research base, encourages rapid uptake of high-throughput platforms and integrated bioinformatics solutions that support translational research and centralized testing networks. Stakeholders in this region prioritize regulatory alignment with local authorities, clinical validation, and evidence generation to support clinical adoption and payer engagement.

Within Europe, Middle East & Africa, diverse regulatory regimes and varying healthcare funding models create differentiated adoption pathways. Western European markets tend to emphasize interoperability, standardized data reporting, and quality systems, while emerging markets in the region focus on access, capacity building, and cost-effective workflows. Collaborative public-private initiatives and regional reference laboratory networks play an outsized role in scaling targeted sequencing for public health and oncology programs.

Asia-Pacific demonstrates rapid capacity expansion driven by public investment, large patient populations, and ambitious precision-medicine initiatives. Several countries are investing heavily in localized manufacturing, domestic R&D, and national genomics programs, which accelerates demand for both benchtop systems for decentralized testing and high-throughput platforms for population-scale studies. Across the region, partnerships between global vendors and local service providers or manufacturers help tailor offerings to regulatory expectations and price sensitivity while advancing technology transfer and workforce development.

Across all regions, cross-border collaboration, data harmonization efforts, and regulatory convergence are emerging themes that support multinational clinical studies and diagnostic rollouts. Regional infrastructure maturity, payer policies, and local manufacturing capabilities continue to shape supplier selection and commercial strategies, underscoring the need for geographically nuanced go-to-market plans.

How specialization in instruments, reagents, and bioinformatics combined with partnerships and service models determines sustainable competitive positioning

Company-level trends reflect a competitive landscape where specialization, integration, and service differentiation determine positioning. Vendors focused on instrument innovation emphasize throughput, automation, and sample-to-answer workflows that reduce hands-on time and enable decentralized testing. Conversely, reagent and kit providers concentrate on assay robustness, lot-to-lot consistency, and ease of integration with multiple platforms to maximize addressable use cases.

Software and service providers are increasingly differentiating on clinical interpretive capabilities, regulatory readiness, and the ability to deliver validated pipelines that meet laboratory accreditation requirements. Managed services, cloud-enabled analytics, and certified reference databases have become important value levers for organizations seeking to outsource complex analytics or to accelerate clinical deployment. Strategic alliances between instrument manufacturers and bioinformatics firms have proliferated to offer bundled solutions that shorten validation timelines and improve customer retention.

Emerging companies and specialized service providers play a crucial role in niche innovation, developing novel chemistries, bespoke capture probes, and highly optimized panels for hard-to-sequence targets. These smaller entities often collaborate with larger partners for scale-up and distribution while retaining agility in product development and customer engagement. Meanwhile, contract research organizations and clinical CROs expand their offerings to include targeted sequencing assay development and sample management services, responding to sponsors' demand for end-to-end trial-ready workflows.

Overall, successful companies combine technical excellence with robust quality systems, clear regulatory strategies, and customer-centric commercialization models. Firms that invest in evidence generation, interoperability, and flexible commercial structures are better positioned to capture long-term value as clinical and research adoption continues to mature.

Practical strategic priorities for leaders to enhance interoperability, regulatory readiness, supply-chain resilience, and evidence-driven commercialization

Industry leaders should pursue a coordinated set of strategic actions to strengthen resilience, accelerate adoption, and capture higher-value opportunities. First, prioritize platform interoperability and open standards so that customers can integrate instruments, reagents, and analytics with minimal friction; this reduces buyer resistance and expands the addressable user base. Second, invest in regulatory and clinical-evidence capabilities early in the product lifecycle to shorten time-to-clinical utility and to support reimbursement discussions.

Third, diversify manufacturing and sourcing footprints to mitigate tariff and geopolitical risk while ensuring consistent supply for critical consumables. Coupled with this, develop flexible commercial models-such as reagent-as-a-service, subscription analytics, or outcome-linked agreements-that align vendor incentives with customers' operational and fiscal objectives. Fourth, strengthen partnerships with clinical laboratories, academic consortia, and pharmaceutical sponsors to co-develop panels and generate real-world evidence that demonstrates utility across diagnostic and therapeutic workflows.

Fifth, prioritize talent development in bioinformatics and assay validation to maintain high analytical standards and to accelerate time-to-insight for customers. Sixth, implement rigorous quality-management systems and documentation practices to streamline regulatory submissions and to facilitate multi-jurisdictional approvals. Finally, adopt a data governance posture that emphasizes interoperability, patient privacy, and secure cloud architectures to enable scalable analytics while preserving compliance.

Collectively, these actions create a durable competitive foundation by aligning product roadmaps with customer needs, regulatory realities, and operational constraints, enabling organizations to convert technical capabilities into sustainable commercial outcomes.

A mixed-methods research framework combining stakeholder interviews, technical literature synthesis, and regulatory review to ensure context-aware actionable insights

This research synthesizes primary and secondary inputs to generate a comprehensive assessment of targeted sequencing dynamics, drawing on structured interviews, technical validation reviews, and cross-regional policy analysis. Primary qualitative interviews were conducted with laboratory directors, assay developers, procurement leaders, and regulatory specialists to capture operational pain points, adoption drivers, and evidence-generation strategies. These conversations informed the interpretation of technical trade-offs across platform architectures and guided recommendations for commercialization and product development.

Secondary inputs included peer-reviewed literature, regulatory guidance documents, clinical-pathway analyses, and published technical performance studies that describe assay sensitivity, specificity, and workflow constraints. The analysis also leveraged publicly available clinical trial registries, patent filings, and conference proceedings to map innovation trajectories and to identify emerging chemistries and analytic approaches. Comparative policy reviews assessed regional regulatory expectations, quality standards, and reimbursement frameworks that influence clinical deployment.

Analytical approaches combined qualitative synthesis with cross-sectional benchmarking of technology attributes, user needs, and regional enablers. Validation steps included triangulating interview insights with technical performance claims and regulatory precedents, ensuring the conclusions reflect real-world implementation considerations. Limitations of the research are acknowledged where proprietary performance data or confidential commercial agreements restrict visibility; where appropriate, recommendations emphasize adaptable strategies that perform under varying evidentiary and regulatory conditions.

This mixed-methods approach produces actionable, context-aware insights intended to support decision-making across R&D planning, commercial strategy, and operational risk management.

Synthesis of strategic imperatives and operational guidance to translate targeted sequencing advancements into durable clinical and commercial impact

In conclusion, targeted sequencing occupies a strategic intersection between technological capability and clinical need, offering focused genomic interrogation that supports diagnostics, therapeutics, and public health applications. Advances in chemistry, instrumentation, and bioinformatics have expanded the technique's utility while driving new commercial models that couple assays with integrated analytics. At the same time, external forces-including regulatory expectations, payer scrutiny, and trade policy-shape how products move from development into routine use.

Stakeholders that align product development with rigorous evidence-generation, adopt supply-chain diversification, and prioritize interoperability will be best positioned to capture sustained value. Regional nuances require tailored strategies: centralized high-throughput approaches work well where regulatory and reimbursement systems support scale, while benchtop and decentralized solutions address demand for rapid, point-of-care decision-making. Finally, companies that combine technical excellence with thoughtful commercial and regulatory execution will find the greatest opportunities to differentiate and to secure long-term partnerships with diagnostic laboratories, healthcare systems, and pharmaceutical sponsors.

This executive summary provides a strategic foundation for leaders seeking to prioritize investments, design collaborative programs, and navigate operational risks in the evolving targeted sequencing landscape. The recommendations and insights herein are intended to support disciplined decision-making and to accelerate the translation of targeted sequencing innovation into measurable clinical and research impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid integration of custom targeted sequencing panels for precision oncology and personalized treatment decision making
  • 5.2. Expansion of multiplexed targeted sequencing assays for comprehensive microbial pathogen detection in clinical labs
  • 5.3. Emergence of single-cell targeted sequencing technologies to resolve cellular heterogeneity in tumor microenvironments
  • 5.4. Implementation of long-read targeted sequencing approaches to detect structural variants and complex genomic rearrangements
  • 5.5. Growth of on-chip microfluidic targeted sequencing platforms enabling high-throughput sample processing and reduced costs
  • 5.6. Increasing application of targeted sequencing in noninvasive prenatal testing for early detection of fetal chromosomal abnormalities
  • 5.7. Advancements in bioinformatic pipelines for enhanced sensitivity and specificity in targeted sequencing data analysis workflows
  • 5.8. Shift toward integrated targeted sequencing and digital pathology solutions for comprehensive molecular diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Sequencing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Benchtop Sequencers
    • 8.1.2. High-Throughput Sequencers
  • 8.2. Reagents & Kits
    • 8.2.1. Amplicon-Based Kits
    • 8.2.2. Hybridization-Based Kits
    • 8.2.3. MIP-Based Kits
  • 8.3. Software & Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Data Analysis Software

9. Targeted Sequencing Market, by Platform

  • 9.1. Amplicon Sequencing
    • 9.1.1. Multiplex PCR
    • 9.1.2. UMI-Based Sequencing
  • 9.2. Hybrid Capture
    • 9.2.1. Baits-Based Capture
    • 9.2.2. Probe-Based Capture
  • 9.3. Molecular Inversion Probes
    • 9.3.1. MIP Probes For CNV Analysis
    • 9.3.2. MIP Probes For SNP Detection

10. Targeted Sequencing Market, by End User

  • 10.1. Academic & Research Institutes
    • 10.1.1. Private Research Labs
    • 10.1.2. Public Research Labs
  • 10.2. Hospitals & Diagnostic Centers
    • 10.2.1. Point-of-Care Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Pharmaceutical & Biotechnology Companies
    • 10.3.1. Clinical Research Organizations
    • 10.3.2. Drug Discovery Units

11. Targeted Sequencing Market, by Application

  • 11.1. Biomarker Discovery
    • 11.1.1. Pharmacogenomic Biomarkers
    • 11.1.2. Predictive Biomarkers
  • 11.2. Genetic Diseases
    • 11.2.1. Prenatal Testing
    • 11.2.2. Rare Disease Diagnosis
  • 11.3. Infectious Diseases
    • 11.3.1. Antibiotic Resistance Testing
    • 11.3.2. Pathogen Detection
  • 11.4. Oncology
    • 11.4.1. Diagnostics
    • 11.4.2. Prognostics
    • 11.4.3. Theranostics

12. Targeted Sequencing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Targeted Sequencing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Targeted Sequencing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Illumina, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Agilent Technologies, Inc.
    • 15.3.4. QIAGEN N.V.
    • 15.3.5. F. Hoffmann-La Roche Ltd
    • 15.3.6. BGI Genomics Co., Ltd.
    • 15.3.7. Twist Bioscience Corporation
    • 15.3.8. Pacific Biosciences of California, Inc.
    • 15.3.9. Oxford Nanopore Technologies plc
    • 15.3.10. NeoGenomics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. TARGETED SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. TARGETED SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TARGETED SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PUBLIC RESEARCH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2024 (USD MILLION)
  • TABLE 304. A